Acne: Hormonal concepts and therapy

Clinics in Dermatology

Volumn 22, Issue 5, 2004, Pages 419-428

  Thiboutot, Diane ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYPROTERONE ACETATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETYNODIOL DIACETATE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; GONADORELIN AGONIST; HYDROCORTISONE; LEVONORGESTREL; MELANOCORTIN; NORETHISTERONE; NORETHISTERONE ACETATE; PRASTERONE SULFATE; SPIRONOLACTONE; TESTOSTERONE;

ACNE VULGARIS; ADRENAL GLAND; ANDROGEN METABOLISM; ANDROGEN RELEASE; ANDROGEN SYNTHESIS; BREAST TENDERNESS; CHOLESTEROL SIDE CHAIN CLEAVAGE; CHOLESTEROL SYNTHESIS; CORTICOTROPIN TEST; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE EXACERBATION; ENDOCRINE DISEASE; ESTROGEN ACTIVITY; FLUID RETENTION; GLUCOSE INTOLERANCE; HEADACHE; HEPATITIS; HIRSUTISM; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERANDROGENISM; HYPOSPADIAS; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE TYPE ALOPECIA; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SEBACEOUS GLAND; TREATMENT CONTRAINDICATION;

EID: 8844250091     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2004.03.010     Document Type: Article

References (73)

1. Choudhry R., Hodgins M., Van der Kwast T., et al. Localization of androgen receptors in human skin by immunohistochemistry implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol. 133:1991;467-475
2. Liang T., Hoyer S., Yu R. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol. 100:1993;663-666
3. Lucky A.W., Biro F.M., Huster G.A., et al. Acne vulgaris in premenarchal girls. Arch Dermatol. 130:1994;308-314
4. Stewart M.E., Downing D.T., Cook J.S., et al. Sebaceous gland activity and serum dehydroepiandrosterone sulfate levels in boys and girls. Arch Dermatol. 128:1992;1345-1348
5. Imperato-McGinley J., Gautier T., Cai L.Q., et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metabol. 76:1993;524-528
6. Pochi P.E., Strauss J.S. Sebaceous gland response in man to the administration of testosterone, D4- androstenedione, and dehydroisoandrosterone. J Invest Dermatol. 52:1969;32-36
7. Marynick S.P., Chakmajian Z.H., McCaffree D.L., et al. Androgen excess in cystic acne. N Engl J Med. 308:1983;981-986
8. Lucky A., McGuire J., Rosenfield R., et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 81:1983;70
9. Chen W., Thiboutot D., Zouboulis C. Cutaneous androgen metabolism basic research and clinical perspectives. J Invest Dermatol. 119:2002;992-1007
10. Labrie F., Luu-The V., Pelletier G., et al. Intracrinology and the skin. Horm Res. 54:2000;213-229
11. Baillie A., Calman K., Milne J. Histochemical distribution of hydroxysteroid dehydrogenases in human skin. Br J Dermatol. 7:1965;610-616
12. Sawaya M.E., Honig J.L.S., Garland L.D., et al. D5-3b-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness. J Invest Dermatol. 91:1988;101-105
13. 4-5-isomerase in human sebaceous glands and their secretory activityin vivo. J Invest Dermatol. 81:1983;139-144
14. Mason J. The 3b-hydroxysteroid dehydrogenase gene family of enzymes. Trends in Endocrin and Metab. 4:1993;199-202
15. Chai Z., Brereton P., Suzuki T., et al. 17 b-hydroxysteroid dehydrogenase type XI localizes to human steroidogenic cells. Endocrinology. 144:2003;2084-2091
16. Andersson S., Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids. 62:1997;143-147
17. Hay J.B., Hodgins M.B., Donnelly J.B. Human skin androgen metabolism and preliminary evidence for its control by two forms of 17 β-hydroxysteroid oxidoreductase. J Endocrinol. 93:1982;403-413
18. Thiboutot D., Martin P., Volikos L., et al. Oxidative activity of the type 2 isozyme of 17b-hydroxysteroid dehydrogenase (17b-HSD) predominates in human sebaceous glands. J Invest Dermatol. 111:1998;390-395
19. Jenkins E.P., Andersson S., Imperato-McGinley J., et al. Genetic and pharmacological evidence for more than one human steroid 5a-reductase. J Clin Invest. 89:1992;293-300
20. Thiboutot D., Harris G., Iles V., et al. Activity of the type 1 5a-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 105:1995;209-214
21. Fritsch M., Orfanos C., Zeboulis C., Sebocytes C. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol. 116:2001;793-800
22. Cassidy D., Lee C., Laker M., et al. Lipogenesis in isolated human sebaceous glands. FEBS Lett. 200:1986;173-176
23. Proksch E., Feingold K.R., Elias P.M. Epidermal HMG CoA reductase activity in essential fatty acid deficiency barrier requirements rather than eicosanoid generation regulate cholesterol synthesis. J Invest Dermatol. 99:1992;216-220
24. Smythe C., Greenall M., Kealey T. The activity of HMG-CoA reductase and acetyl- CoA carboxylase in human apocrine sweat glands, sebaceous glands and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol. 111:1998;139-148
25. Sugawara T., Lin D., Holt J.A., et al. Structure of the human steroidogenic acute regulatory protein (StAR) gene StAR stimulates mitochondrial cholesterol 27-hydroxylase activity. Biochemistry. 34:1995;12506-12512
26. Watari H., Arakane F., Moog-Lutz C., et al. MLN64 contains a domain with homology to the steroidogenic acute regulatory protein (StAR) that stimulates steroidogenesis. Proc Natl Acad Sci U S A. 94:1997;8462-8467
27. Black S.M., Szklarz G.D., Harikrishna J.A., et al. Regulation of proteins in the cholesterol side-chain cleavage system in JEG-3 and Y-1 cells. Endocrinology. 132:1993;539-545
28. Rosenfield R., Barnes R., Carr J., et al. Dysregulation of cytochrome P450c17 as the cause of polycystic ovarian syndrome. Fertil Steril. 53:1990;785-791
29. Parker K.L., Schimmer B.P. Steroidogenic factor 1 a key determinant of endocrine development and function. Endocr Rev. 18:1997;361-377
30. Patel M., McKay I., Burrin J. Transcriptional regulators of steroidogenesis, DAX-1 and SF-1 are expressed in human skin. J Invest Dermatol. 117:2001;1559-1565
31. Thiboutot D., Jabara S., McAllister J., et al. Human skin is a steroidogenic tissue steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol. 120:2003;905-914
32. Labrie F., Simard J., Luu-The V., et al. Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. Baillieres Clin Endocrinol Metabol. 8:1994;451-474
33. Zouboulis C. Human skin an independent peripheral endocrine organ. Horm Res. 54:2000;230-242
34. Strauss J., Kligman A. Effect of cyclic progestin-estrogen therapy on sebum and acne in women. JAMA. 190:1964;815-819
35. Sawaya M.E., Price V.H. Different levels of 5a-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 109:1997;296-300
36. Rosenfield R.L., Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med. 98:(Suppl 1A):1995;1A80S-1A88S
37. Laurent S., Mednieks M., Rosenfield R. Growth of sebaceous cells in monolayer culture in vitro. Cell Dev Biol. 28A:(2):1992;83-89
38. Deplewski D., Rosenfield R.L. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. 140:1999;4089-4094
39. Hodak E., Gottlieb A., Anzilotti M., et al. The insulin-like growth factor I receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages correlation of increased expression with epidermal hyperplasia. J Invest Dermatol. 106:1996;564-570
40. Danilenko D., Ring B., Yanagihara D., et al. Keratinocyte growth factor is an important endogenous mediator of hair follicle growth, development and differentiation. Am J Pathol. 147:1995;145-154
41. Pierce G., Yanagihara D., Klopchin K., et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med. 179:1994;831-840
42. Akimoto N., Sato T., Sakiguchi T., et al. Cell proliferation and lipid formation in hamster sebaceous gland cells. Dermatology. 204:2002;118-123
43. Chen W., Kelly M., Opitz-Araya X., et al. Exocrine gland dysfunction in MC5-R-deficient mice evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell. 91:1997;789-798
44. van der Kraan M., Adan R., Entwistle M., et al. Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology. 139:1998;2348-2355
45. Thiboutot D., Sivarajah A., Gilliland K., et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol. 115:2000;614-619
46. Hatta N., Dixon C., Ray A., et al. Expression, candidate gene, and population studies of the melanocortin 5 receptor. J Invest Dermatol. 116:2001;564-570
47. Stander S., Bohm M., Brzoska T., et al. Expression of melanocortin-1 receptor in normal, malformed and neoplastic skin glands and hair follicles. Exp Dermatol. 11:2002;42-51
48. Slominski A., Ermak G., Hwang J., et al. Proopiomelanocortin, corticotrophin-releasing hormone and corticotrophin-releasing hormone receptor genes are expressed in human skin. FEBS Lett. 374:1995;113-116
49. Zouboulis C., Seltmann H., Hiroi N., et al. Corticotrophin-releasing hormone an autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci. 99:2002;7148-7153
50. Thiboutot D., Gilliland K., Light J., et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 135:1999;1041-1045
51. Shaw J. Spironolactone in dermatologic therapy. J Am Acad Dermatol. 24:1991;236-243
52. Lubbos H.G., Hasinski S., Rose L.I., et al. Adverse effects of spironolactone therapy in women with acne [letter]. Arch Dermatol. 134:1998;1162-1163
53. Stewart M.E., Greenwood R., Cunliffe W.J., et al. Effect of cyproterone acetate-ethinyl estradiol treatment on the proportions of linoleic and sebaleic acids in various skin surface lipid classes. Arch Dermatol Res. 278:1986;481-485
54. Dodin S., Faure N., Cedrin I., et al. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol. 43:1995;575-582
55. Wysowski D., Freiman J., Tourtelot J., et al. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Int Med. 118:1993;860-864
56. Thorneycroft I.H., Stanczyk F.Z., Bradshaw K.D., et al. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception. 60:1999;255-262
57. Leyden J.J. Therapy for acne vulgaris. New Engl J Med. 336:1997;1156-1162
58. Thorneycroft I. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med. 47:(Suppl 11):2002;975-980
59. van Vloten W., van Haselen C., van Zuuren E., et al. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 69:(Suppl 4):2002;2-15
60. Greenwood R., Brummitt L., Burke B., et al. Acne double-blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J. 291:1985;1231-1235
61. Lemay A., Dewailly S.D., Grenier R., et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 71:1990;8-14
62. Lucky A., Henderson T., Olson W., et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 37:1997;746-754
63. Redmond G.P., Olson W.H., Lippman J.S., et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris a randomized, placebo-controlled trial. Obstet Gynecol. 89:1997;615-622
64. Thiboutot D., Archer D., Lemay A., et al. A randomized, controlled trial of a low-dose contraceptive containing 20 mg of ethinylestradiol and 100 mg of levonorgestrel for acne treatment. Fertil Steril. 76:2001;461-468
65. Leyden J., Shalita A., Hordinsky M., et al. Efficacy of a low-dose oral contraceptive containing 20 mg of ethinyl estradiol and 100 mg of levonorgestrel for the treatment of moderate acne a randomized, placebo-controlled trial. J Am Acad Dermatol. 47:2002;399-409
66. Maloney M., Arbit D., Flack M., et al. Use of a low-dose oral contraceptive containing norethindrone acetate and ethinyl estradiol in the treatment of moderate acne vulgaris. Clin J Womens Health. 1:2001;124-131
67. Archer J., Archer D. Oral contraceptive efficacy and antibiotic interaction a myth debunked. J Am Acad Dermatol. 46:2002;917-923
68. Weaver K., Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception. 59:1999;71-78
69. Helms S.E., Bredle D.L., Zajic J., et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 36:(5 Pt 1):1997;705-710
70. London B.M., Lookingbill D.P. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives [letter]. Arch Dermatol. 130:1994;392-393
71. Dittrich R., Parker L., Rosen J., et al. Transdermal contraception evaluation of three transdermal norelgestromin/ethinyl estradiol doses in a randomized, multicenter, dose-response study. Am J Obstet Gynecol. 186:2002;15-20
72. Bjarnadottir R., Tuppurainen M., Killick S. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol. 186:2002;389-395
73. Kaunitz A.M., Garceau R., Cromie M. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group. Contraception. 60:1999;179-187